Cited by 106Parkinson's Disease Mechanisms and TreatmentsNeurological disorders and treatmentsDementia and Cognitive Impairment Research

Functional neurological disorders in Parkinson disease

Open access
Wissel, Benjamin D, Dwivedi, Alok K, Merola, Aristide, Chin, Danielle, Jacob, Cara, Duker, Andrew P, Vaughan, Jennifer E, Lovera, Lilia +13 more·2018·Journal of Neurology, Neurosurgery & Psychiatry

Abstract

Objective: To ascertain demographic and clinical features of Parkinson disease (PD) associated with functional neurological features. Methods: A standardised form was used to extract data from electronic records of 53 PD patients with associated functional neurological disorders (PD-FND) across eight movement disorders centres in the USA, Canada and Europe. These subjects were matched for age, gender and disease duration to PD patients without functional features (PD-only). Logistic regression analysis was used to compare both groups after adjusting for clustering effect. Results: Functional symptoms preceded or co-occurred with PD onset in 34% of cases, nearly always in the most affected body side. Compared with PD-only subjects, PD-FND were predominantly female (68%), had longer delay to PD diagnosis, greater prevalence of dyskinesia (42% vs 18%; P=0.023), worse depression and anxiety (P=0.033 and 0.025, respectively), higher levodopa-equivalent daily dose (972±701 vs 741±559 mg; P=0.029) and lower motor severity (P=0.019). These patients also exhibited greater healthcare resource utilisation, higher use of [(123)I]FP-CIT SPECT and were more likely to have had a pre-existing psychiatric disorder (P=0.008) and family history of PD (P=0.036). Conclusions: A subtype of PD with functional neurological features is familial in one-fourth of cases and associated with more psychiatric than motor disability and greater use of diagnostic and healthcare resources than those without functional features. Functional manifestations may be prodromal to PD in one-third of patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jnnp-2017-317378

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Studies of Parkinson's disease are increasingly highlighting FND as a comorbidity, especially in the prodromal period.

    “studies of Parkinson’s disease are increasingly highlighting FND as a comorbidity, especially in the prodromal period [40]”

    From Functional neurological disorder and multiple sclerosis: a systematic review of misdiagnosis and clinical overlap (2022) · cites this paper as [40]

    The Introduction describes FND co-occurring with Parkinson disease, and the Characteristics of the functional phenotype section reports that FND symptoms preceded PD diagnosis in 26% of the PD-FND cohort. But FND began after PD diagnosis in 57%, so the paper does not support the emphasis on the prodromal period; preceding diagnosis also does not establish that symptoms arose before PD itself. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • FND comorbidity is well recognized for other neurological conditions.

    “This kind of FND comorbidity is well recognized for other neurological conditions.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 16

  1. Dr. Lang has served as an advisor for AbbVie, Allon Therapeutics, Avanir Pharmaceuticals, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Ceregene, Cipla, InteKrin, Lilly, Medtronic, Merck, Novartis, NeuroPhage Pharmaceuticals, Teva, and UCB; received honoraria from Medtronic, Teva, UCB, and AbbVie; received grants from Brain Canada, the Canadian Institutes of Health Research, the Edmond J. Safra Philanthropic Foundation, The Michael J. Fox Foundation, the Ontario Brain Institute, National Parkinson Foundation, Parkinson Society Canada, Physicians Services Incorporated (PSI), Tourette Syndrome Association, W. Garfield Weston Foundation; received publishing royalties from Saunders, Wiley-Blackwell, Johns Hopkins Press, and Cambridge University Press; and has served as an expert witness in cases related to the welding industry.
  2. Dr. Morgante has received honoraria as a Consultant & Advisory Boards from Medtronic, UCB and Chiesi. She has received honoraria for speaking from UCB Pharma, Medtronic, Zambon, Chiesi, Abbvie. She serves on the Editorial board of Movement Disorders Clinical Practice and Frontiers in Movement Disorders. She receives royalties from publication ot Disorders of Movement (Springer, 2016).
  3. Dr. Bhatia has received grant support from Welcome/MRC, NIHR, Parkinsons's UK and EU Horizon 2020. He has received royalties from publication of the Oxford Specialist Handbook Parkinson's Disease and Other Movement Disorders (Oxford University Press, 2008, 2016) and of Marsden's Book of Movement Disorders (Oxford University Press, 2013). He has received honoraria/personal compensation for participating as consultant/scientific board member from
  4. Neurotechnologies, Davis Phinney Foundation, and the Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Solvay, Abbott, Chelsea Therapeutics, TEVA, Impax, Merz, Lundbeck, and Eli Lilly; honoraria from TEVA, UCB, the American Academy of Neurology, and the Movement Disorders Society; and publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer. Wissel 18
  5. Stone J, Carson A, Duncan R, et al. Which neurological diseases are most likely to be associated with "symptoms unexplained by organic disease". J Neurol 2012;259(1):33-8.
  6. Wissel BD, Dwivedi AK, Gaston TE, et al. Which patients with epilepsy are at risk for psychogenic nonepileptic seizures (PNES)? A multicenter case-control study. Epilepsy Behav 2016;61:180-4.
  7. Onofrj M, Bonanni L, Manzoli L, et al. Cohort study on somatoform disorders in Parkinson disease and dementia with Lewy bodies. Neurology 2010;74(20):1598-606.
  8. Onofrj M, Thomas A, Tiraboschi P, et al. Updates on Somatoform Disorders (SFMD) in Parkinson's Disease and Dementia with Lewy Bodies and discussion of phenomenology. J Neurol Sci 2011;310(1-2):166-71.
  9. Espay AJ, Lang AE. Phenotype-specific diagnosis of functional (psychogenic) movement disorders. Curr Neurol Neurosci Rep 2015;15(6):32.
  10. Parees I, Saifee TA, Kojovic M, et al. Functional (psychogenic) symptoms in Parkinson's disease. Mov Disord 2013;28(12):1622-7.
  11. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17(5):427-42.
  12. Gupta A, Lang AE. Psychogenic movement disorders. Curr Opin Neurol 2009;22(4):430-6.
  13. Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25(15):2649-53.
  14. Anderson KE, Gruber-Baldini AL, Vaughan CG, et al. Impact of psychogenic movement disorders versus Parkinson's on disability, quality of life, and psychopathology. Mov Disord 2007;22(15):2204-9.
  15. Siri C, Cilia R, De Gaspari D, et al. Psychiatric symptoms in Parkinson's disease assessed with the SCL-90R self-reported questionnaire. Neurol Sci 2010;31(1):35-40.
  16. Schrag A, Brown RJ, Trimble MR. Reliability of self-reported diagnoses in patients with neurologically unexplained symptoms. J Neurol Neurosurg Psychiatry 2004;75(4):608-11.

Cited by

Sorted by citations

Authors
Wissel, B. D., Dwivedi, A. K., Merola, A., Chin, D., Jacob, C., Duker, A. P., Vaughan, J. E., Lovera, L., LaFaver, K., Levy, A., Lang, A. E., Morgante, F., Nirenberg, M. J., Stephen, C., Sharma, N., Romagnolo, A., Lopiano, L., Balint, B., Yu, X. X., Bhatia, K. P., & Espay, A. J.
Affiliations
  • University of Cincinnati (US)
  • Texas Tech University Health Sciences Center (US)
  • University of Louisville (US)
  • University of Toronto (CA)
  • University of Messina (IT)
  • NYU Langone Health (US)
  • Harvard University (US)
  • University of Turin (IT)
  • University Hospital Heidelberg (DE)
  • Cleveland Clinic (US)
  • University College London (GB)
Corresponding author
Espay, Alberto J
Venue
Journal of Neurology, Neurosurgery & Psychiatry
Publisher
BMJ
Published
2018-03-16
Volume
89
Issue
6
Pages
566-571
ISSN
  • 0022-3050 (ISSN-L)
  • 1468-330X
OpenAlex
W2789418298
Cited by
106
References
2
Citations by year
2026: 3 · 2025: 14 · 2024: 15 · 2023: 16 · 2022: 17 · 2021: 15 · 2020: 14 · 2019: 10 · 2018: 2
FWCI
6.96
Type
journal article
Language
en
Open access
Locations
  • Journal of Neurology Neurosurgery & Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • National Institutes of Health (KL2TR001426)
  • National Heart, Lung, and Blood Institute (R01HL125016)
  • National Institute of General Medical Sciences (T32GM063483)
  • National Institute of Allergy and Infectious Diseases (R21AI118228)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Neurology › Neurological disorders and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Parkinson's disease, conversion disorder, prodromal Parkinson's disease, dyskinesia, depression, anxiety, levodopa equivalent daily dose, motor impairment severity, psychiatric comorbidity, health care utilization, 123I-FP-CIT SPECT, delayed diagnosis
MeSH terms
Aged, Antiparkinson Agents, Female, Humans, Male, Middle Aged, Nervous System Diseases, Parkinson Disease, Risk Factors, Prevalence, Case-Control Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review